Latest from Dana Farber

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.
Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status. 
 
Kathleen Mahoney, MD, PhD, discusses the potential of targeting V-domain immunoglobulin containing suppressor of T-cell activation in renal cell carcinoma. 
 
Bradley McGregor, MD, discusses the challenges of developing treatment strategies for patients with non-cell clear renal cell carcinoma. 
 
Bradley McGregor, MD, discusses the most impactful trials in prostate cancer presented at the 2019 ESMO Congress. 
 
Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer. 
 
Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.
Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.
Publication Bottom Border
Border Publication
x